

PharmStars Announces the First Startup from Australia to Graduate from its Accelerator Program: Preview Health

PharmStars, the pharma-focused accelerator for digital health startups, announces the graduation of Preview Health, the first Australian startup in the program.

BOSTON, MA, UNITED STATES, July 1, 2025 /EINPresswire.com/ --

[PharmStars](#), the pharma-focused accelerator for digital health startups, is delighted to announce that [Preview Health](#) is the first Australian startup to graduate from the program. Preview Health of Sydney, Australia, successfully completed PharmaU, PharmStars' 10-week educational and mentoring program in May 2025. They are one of 12 startups to graduate from PharmStars' Spring 2025 cohort, which focused on "Digital Innovations in Rare Disease." The culmination of the PharmStars accelerator was a Showcase Event in Boston at which Preview Health presented to and met one-on-one with PharmStars' innovation-minded pharma members.

PharmStars is dedicated to bridging the "[pharma-startup gap](#)." The accelerator's mission is to help biopharma and digital health startups overcome cultural and other barriers to partnership, thereby accelerating the adoption of digital innovations to improve patient outcomes. PharmaU prepares participating startups to effectively engage with pharma companies as clients and partners.

The Spring 2025 cohort was PharmStars' eighth cohort. Preview Health — the first Australian startup to participate in PharmStars — was selected in March 2025 following a highly competitive application process that attracted startups from 10 countries. Each of the 12 selected startups offers a unique digital health solution for pharma related to rare disease.



Preview Health is the First Australian Startup to Graduate from PharmStars

Naomi Fried, the CEO of PharmStars, said, “We were thrilled to have Preview Health as the first Australian company to graduate from PharmStars. I’m confident that pharmaceutical companies around the world will find their cutting-edge AI platform for comprehensive metabolic profiling extremely valuable for improving disease prediction and diagnosis.”

Preview Health’s proprietary AI platform analyzes 100% of detectable metabolites, capturing the full spectrum of individual metabolic responses. It integrates seamlessly into pharma workflows by using existing biospecimens (e.g., blood, urine) and equipment (i.e., mass spectrometry).

Preview Health provides personalized metabolic response profiles. To date, this platform has uncovered dozens of novel biomarkers for respiratory diseases, infection, and chronic pain, demonstrating significantly enhanced diagnostic accuracy. Pharmaceutical companies can use their AI platform for drug safety and efficacy testing and to gain a comprehensive understanding of patients’ metabolic response.

After recognizing their product could enhance current diagnostics, Preview Health identified pharma as a promising — though difficult to access — market. On the recommendation of a mentor, they applied to PharmStars and were excited to be accepted into the program. Diana Zhang, founder and CEO of Preview Health, and a PharmStars Spring 2025 graduate, shared how valuable the experience was for them: “PharmStars is a 10-week comprehensive education about the pharmaceutical industry with a fast-tracked opportunity to engage industry stakeholders and meet with pharma — which is priceless.”

Preview Health found the PharmStars program helpful in engaging potential pharmaceutical customers. Anastasia Latin, co-founder and COO of Preview Health and a PharmStars Spring 2025 graduate, said, “Before going through PharmaU, we never felt fully prepared going into conversations with pharma. PharmStars provides the education needed to confidently interact with pharma. But it's not just an educational program. We got invaluable opportunities to talk directly with, and receive feedback from, pharmaceutical companies in the fireside chats and the one-on-one Showcase conversations.”

As an Australian-based startup, participating in PharmStars proved to be beneficial, as Anastasia Latin shared, “Startups outside the US understand that different pharma companies may or may not be accessible to you depending on your location. Since the US is the hub of pharmaceutical companies, participating in a US-based pharma-focused accelerator program was hugely valuable, teaching us to navigate the US pharma systems and opening that market up for us.”

PharmStars is accepting applications for its upcoming Fall 2025 cohort, focused on “Innovations in Data Management & Insights,” until July 13, 2025. Digital health startups interested in participating can find additional details and the application on the PharmStars’ website, www.PharmStars.com.

About PharmStars □

PharmStars is the member-based, pharma-focused accelerator for digital health startups. Because of our expertise across pharma, startups, digital health, and innovation, we understand the challenges that pharma and startups face when seeking to collaborate. Our PharmaUTM program supports digital health startups and our pharma members in “bridging the pharma-startup gap,” leading to greater success and faster adoption of “beyond the molecule” solutions. More information at www.PharmStars.com.

About Preview Health

Preview Health’s proprietary AI platform analyzes 100% of detectable metabolites from standard biospecimens using existing mass spectrometry workflows. They enable personalized metabolic response profiles to stratify patient responders, optimize dosing, and identify novel biomarkers and exploratory endpoints. Preview Health’s platform has uncovered dozens of novel biomarkers in respiratory disease, infection, and chronic pain, significantly improving diagnostic accuracy. Published results include the prediction of early-stage Parkinson’s disease with 96% accuracy and stratification of chronic pain subtypes with 98% precision. Preview Health’s platform improves methods for analyzing drug safety and efficacy, providing a complete understanding of the metabolic response, particularly in small, heterogeneous, rare disease populations.

Preview Health

www.preview.health

team@preview.health

www.linkedin.com/company/previewhealth

PharmStars

www.PharmStars.com

+1 617-333-8723

info@pharmstars.com

Visit us on social media:

[LinkedIn](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/826358217>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.